Beam Therapeutics Inc. Share-based Payment Arrangement, Expense
Beam Therapeutics Inc. (BEAM) reported Share-based Payment Arrangement, Expense of $19.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-04
- Beam Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $19.28M, a 20.88% decline year-over-year.
- Beam Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $19.04M, a 28.63% decline year-over-year.
- Beam Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $20.45M, a 32.33% decline year-over-year.
- Beam Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $22.75M, a 23.05% decline year-over-year.
- Beam Therapeutics Inc. share-based payment arrangement, expense for fiscal 2025 was $94.24M, a 21.89% decline from fiscal 2024.
- Beam Therapeutics Inc. share-based payment arrangement, expense for fiscal 2024 was $120.66M, a 22.32% increase from fiscal 2023.
- Beam Therapeutics Inc. share-based payment arrangement, expense for fiscal 2023 was $98.65M, a 16.99% increase from fiscal 2022.
- Beam Therapeutics Inc. share-based payment arrangement, expense for fiscal 2022 was $84.32M, a 93.53% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.28M 10-Q · filed 2026-08-04 | $38.32M 10-Q · filed 2026-08-04 | $58.77M derived: sum of 3 quarters · filed 2026-08-04 | $81.52M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $19.04M 10-Q · filed 2026-05-07 | $39.49M derived: sum of 2 quarters · filed 2026-05-07 | $62.24M derived: sum of 3 quarters · filed 2026-05-07 | $86.61M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $20.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $43.20M derived: sum of 2 quarters · filed 2026-02-24 | $67.56M derived: sum of 3 quarters · filed 2026-08-04 | $94.24M 10-K · filed 2026-02-24 |
| 2025-09-30 | $22.75M 10-Q · filed 2025-11-04 | $47.11M derived: sum of 2 quarters · filed 2026-08-04 | $73.80M 10-Q · filed 2025-11-04 | $104.01M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $24.37M 10-Q · filed 2026-08-04 | $51.05M 10-Q · filed 2026-08-04 | $81.27M derived: sum of 3 quarters · filed 2026-08-04 | $110.83M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $26.68M 10-Q · filed 2026-05-07 | $56.90M derived: sum of 2 quarters · filed 2026-05-07 | $86.46M derived: sum of 3 quarters · filed 2026-05-07 | $118.06M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $30.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $59.78M derived: sum of 2 quarters · filed 2026-02-24 | $91.38M derived: sum of 3 quarters · filed 2026-02-24 | $120.66M 10-K · filed 2026-02-24 |
| 2024-09-30 | $29.56M 10-Q · filed 2025-11-04 | $61.16M derived: sum of 2 quarters · filed 2025-11-04 | $90.44M 10-Q · filed 2025-11-04 | $113.06M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $31.60M 10-Q · filed 2025-08-05 | $60.88M 10-Q · filed 2025-08-05 | $83.50M derived: sum of 3 quarters · filed 2026-02-24 | $109.34M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $29.28M 10-Q · filed 2025-05-06 | $51.90M derived: sum of 2 quarters · filed 2026-02-24 | $77.73M derived: sum of 3 quarters · filed 2026-02-24 | $104.01M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $22.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $48.45M derived: sum of 2 quarters · filed 2026-02-24 | $74.73M derived: sum of 3 quarters · filed 2026-02-24 | $98.65M 10-K · filed 2026-02-24 |
| 2023-09-30 | $25.84M 10-Q · filed 2024-11-05 | $52.11M derived: sum of 2 quarters · filed 2024-11-05 | $76.03M 10-Q · filed 2024-11-05 | $98.53M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $26.28M 10-Q · filed 2024-08-06 | $50.20M 10-Q · filed 2024-08-06 | $72.69M derived: sum of 3 quarters · filed 2025-02-25 | $94.90M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $23.92M 10-Q · filed 2024-05-07 | $46.42M derived: sum of 2 quarters · filed 2025-02-25 | $68.63M derived: sum of 3 quarters · filed 2025-02-25 | $90.20M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $22.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $44.71M derived: sum of 2 quarters · filed 2025-02-25 | $66.29M derived: sum of 3 quarters · filed 2025-02-25 | $84.32M 10-K · filed 2025-02-25 |
| 2022-09-30 | $22.21M 10-Q · filed 2023-11-08 | $43.79M derived: sum of 2 quarters · filed 2023-11-08 | $61.82M 10-Q · filed 2023-11-08 | $77.32M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $21.58M 10-Q · filed 2023-08-08 | $39.61M 10-Q · filed 2023-08-08 | $55.12M derived: sum of 3 quarters · filed 2024-02-27 | $68.08M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $18.04M 10-Q · filed 2023-05-10 | $33.54M derived: sum of 2 quarters · filed 2024-02-27 | $46.51M derived: sum of 3 quarters · filed 2024-02-27 | $56.96M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $15.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $28.47M derived: sum of 2 quarters · filed 2024-02-27 | $38.92M derived: sum of 3 quarters · filed 2024-02-27 | $43.57M 10-K · filed 2024-02-27 |
| 2021-09-30 | $12.97M 10-Q · filed 2022-11-07 | $23.42M derived: sum of 2 quarters · filed 2022-11-07 | $28.07M 10-Q · filed 2022-11-07 | $34.88M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $10.45M 10-Q · filed 2022-08-09 | $15.10M 10-Q · filed 2022-08-09 | $21.91M derived: sum of 3 quarters · filed 2023-02-28 | $24.92M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $4.65M 10-Q · filed 2022-05-09 | $11.46M derived: sum of 2 quarters · filed 2023-02-28 | $14.47M derived: sum of 3 quarters · filed 2023-02-28 | $17.24M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $6.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $9.82M derived: sum of 2 quarters · filed 2023-02-28 | $12.59M derived: sum of 3 quarters · filed 2023-02-28 | $15.38M 10-K · filed 2023-02-28 |
| 2020-09-30 | $3.01M 10-Q · filed 2021-11-08 | $5.78M derived: sum of 2 quarters · filed 2021-11-08 | $8.57M 10-Q · filed 2021-11-08 | $10.63M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $2.77M 10-Q · filed 2021-08-10 | $5.56M 10-Q · filed 2021-08-10 | $7.62M derived: sum of 3 quarters · filed 2022-02-28 | $9.65M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $2.79M 10-Q · filed 2021-05-11 | $4.85M derived: sum of 2 quarters · filed 2022-02-28 | $6.88M derived: sum of 3 quarters · filed 2022-02-28 | $8.95M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $4.09M derived: sum of 2 quarters · filed 2022-02-28 | $6.16M derived: sum of 3 quarters · filed 2022-02-28 | $7.03M 10-K · filed 2022-02-28 |
| 2019-09-30 | $2.03M 10-Q · filed 2020-11-10 | $4.10M derived: sum of 2 quarters · filed 2020-11-10 | $4.97M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $2.07M 10-Q · filed 2020-08-12 | $2.94M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $869.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |